Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Hans, Guehring"'
Autor:
Asger Reinstrup Bihlet, Torben Balchen, Kosalaram Goteti, Jesper Sonne, Christoph Ladel, Morten Asser Karsdal, Victor Ona, Flavie Moreau, Roseann Waterhouse, Anne‐Christine Bay‐Jensen, Hans Guehring
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 4, Pp 205-213 (2024)
Objective To assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple injections of M6495, a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS‐5) nanobody, in healthy volunteers and patients wi
Externí odkaz:
https://doaj.org/article/59a53152c87d4341ac5e68cc12a2ad20
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 1, Pp 38-48 (2023)
Objective Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of
Externí odkaz:
https://doaj.org/article/fbfb7923863e4170999f2062f9b263dc
Autor:
Arnaud Briat, Claire Jacques, Mélodie Malige, Laure Sudre, Geoffroy Nourissat, Philippe Auzeloux, Hans Guehring, Florent Cachin, Francis Berenbaum, Elisabeth Miot-Noirault
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract With the emergence of disease modifying osteoarthritis drugs (DMOAD), imaging methods to quantitatively demonstrate their efficacy and to monitor osteoarthritis progression at the functional level are urgently needed. Our group showed that a
Externí odkaz:
https://doaj.org/article/46cfa10ea81e452cb5cdb16ba745afab
Autor:
Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Bente Juhl Riis, Claus Christiansen, Martin Michaelis, Hans Guehring, Christoph Ladel, Morten A. Karsdal
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM le
Externí odkaz:
https://doaj.org/article/f2558c7d1f10478b8c5f1554b53e37d1
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology. 5:38-48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b9466da0aa9a79b3ec812df5812e5ab
https://doi.org/10.1002/acr2.11511
https://doi.org/10.1002/acr2.11511
Autor:
Xavier Montalban, Jerry S. Wolinsky, Douglas L. Arnold, Martin S. Weber, Karolina Piasecka-Stryczynska, Davorka Tomic, Andrea Seitzinger, Hans Guehring
Publikováno v:
Monday, April 24.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c4919e0d07db04f8d2431c88f9c61e5
https://doi.org/10.1212/wnl.0000000000203500
https://doi.org/10.1212/wnl.0000000000203500
Autor:
Christoph Ladel, Yunyun Luo, Angela A. Manginelli, M. Michaelis, Hans Guehring, Anne-Christine Bay-Jensen, Yi He, Morten A. Karsdal
Publikováno v:
Osteoarthritis and Cartilage. 30:92-99
Osteoarthritis (OA) is characterized by the gradual loss of cartilage. Sprifermin, a recombinant FGF18, is being developed as a cartilage anabolic drug. PRO-C2 is a serum marker of type II collagen formation and low levels have been shown to be progn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da02a15c13fd1a63c7d482de320e60d
https://doi.org/10.1016/j.joca.2021.10.008
https://doi.org/10.1016/j.joca.2021.10.008
Autor:
Daniel J, Wallace, Thomas, Dörner, David S, Pisetsky, Jorge, Sanchez-Guerrero, Anand C, Patel, Dana, Parsons-Rich, Claire, Le Bolay, Elise E, Drouin, Amy H, Kao, Hans, Guehring, Maria, Dall'Era
Publikováno v:
ACR open rheumatologyREFERENCES.
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c914e887bef8a0fc2d37ee1efc59306
https://pubmed.ncbi.nlm.nih.gov/36530019
https://pubmed.ncbi.nlm.nih.gov/36530019
Autor:
Suzanne Stewart, Honey Hendesi, Hans Guehring, Michelle L Gibison, Dean W. Richardson, George R. Dodge
Publikováno v:
J Orthop Res
Post-traumatic osteoarthritis is a disabling condition impacting the mostly young and active population. In the present study, we investigated the impact of intra-articular sprifermin, a recombinant truncated fibroblast growth factor 18, on the outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::496c091a202885f36ae69893aee3b6c2
https://doi.org/10.1002/jor.25063
https://doi.org/10.1002/jor.25063
Autor:
Wolfgang Wirth, Benjamin Daelken, Christoph Ladel, Asger Reinstrup Bihlet, Hans Guehring, Flavie Moreau, Philip G. Conaghan, Felix Eckstein, Oliver Guenther, Marc C. Hochberg
Publikováno v:
Seminars in Arthritis and Rheumatism. 51:450-456
Objective To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin. Methods Patients were randomised 1:1:1:1:1 to: sprifermi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17221db3921961a47d753bf82a996f1d
https://doi.org/10.1016/j.semarthrit.2021.03.005
https://doi.org/10.1016/j.semarthrit.2021.03.005